Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injury

Toxicology Letters

Volumn 224, Issue 2, 2014, Pages 215-224

  Matsuo, Kentaro ^a   Sasaki, Eita ^a   Higuchi, Satonori ^a   Takai, Shohei ^a   Tsuneyama, Koichi ^b   Fukami, Tatsuki ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a,c  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Azathioprine; Inflammation; Liver injury; Model mouse; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CARBONYL DERIVATIVE; GLUTATHIONE; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFECT; FEMALE; IMMUNE SYSTEM; INFLAMMATION; LIVER INJURY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TOXIC HEPATITIS;

AZATHIOPRINE; INFLAMMATION; LIVER INJURY; MODEL MOUSE; OXIDATIVE STRESS;

ANIMALS; AZATHIOPRINE; CARRIER PROTEINS; DRUG-INDUCED LIVER INJURY; FEMALE; GLUTATHIONE; IMMUNITY, INNATE; INFLAMMATION; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA; XANTHINE OXIDASE;

EID: 84888164502     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.10.025     Document Type: Article

References (43)

1. Agarwal R., MacMillan-Crow L.A., Rafferty T.M., Saba H., Roberts D.W., Fifer E.K., James L.P., Hinson J.A. Acetaminophen-induced hepatotoxicity in mice occurs with inhibition of activity and nitration of mitochondrial manganese superoxide dismutase. J. Pharmacol. Exp. Ther. 2011, 337:110-116.
2. Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20:319-325.
3. Aithal G.P. Hepatotoxicity related to antirheumatic drugs. Nat. Rev. Rheumatol. 2011, 7:139-150.
4. Amin A., Hamza A.A. Hepatoprotective effects of Hibiscus, Rosmarinus and Salvia on azathioprine-induced toxicity in rats. Life Sci. 2005, 77:266-278.
5. Ansari A., Elliott T., Baburajan B., Mayhead P., O'Donohue J., Chocair P., Sanderson J., Duley J. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008, 28:734-741.
6. Antoine D.J., Williams D.P., Kipar A., Jenkins R.E., Regan S.L., Sathish J.G., Kitteringham N.R., Park B.K. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 2009, 112:521-531.
7. Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 2008, 223:20-38.
8. Bajt M.L., Farhood A., Jaeschke H. Effects of CXC chemokines on neutrophil activation and sequestration in hepatic vasculature. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 281:G1188-G1195.
9. Dejaco C., Mittermaier C., Reinisch W., Gasche C., Waldhoer T., Strohmer H., Moser G. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2003, 121:1048-1053.
10. Dubinsky M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy and safety. Clin. Gastroenterol. Hepatol. 2004, 2:731-743.
11. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., Targan S.R., Vasiliauskas E.A. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915.
12. El-Beshbishy H.A., Tork O.M., El-Bab M.F., Autifi M.A. Antioxidant and antiapoptotic effects of green tea polyphenols against azathioprine-induced liver injury in rats. Pathophysiology 2011, 18:125-135.
13. Fridovich I. Superoxide dismutases. An adaptation to a paramagnetic gas. J. Biol. Chem. 1989, 264:7761-7764.
14. Hennessy E.J., Parker A.E., O'Neill L.A. Targeting Toll-like receptors: emerging therapeutics. Nat. Rev. Drug. Discov. 2010, 9:293-307.
15. Higuchi S., Kobayashi M., Yano A., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. J. Appl. Toxicol. 2012, 32:815-822.
16. Higuchi S., Kobayashi M., Yoshikawa Y., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. IL-4 mediates dicloxacillin-induced liver injury in mice. Toxicol. Lett. 2011, 200:139-145.
17. Higuchi S., Yano A., Takai S., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol. Sci. 2012, 130:4-16.
18. Hisamuddin I.M., Wehbi M.A., Yang V.W. Pharmacogenetics and diseases of the colon. Curr. Opin. Gastroenterol. 2007, 23:60-66.
19. Holt M.P., Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006, 8:48-54.
20. Jeurissen M.E., Boerbooms A.M., van de Putte L.B., Kruijsen M.W. Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis. Ann. Rheum. Dis. 1990, 49:25-27.
21. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 2003, 8:223-246.
22. Kita H., Mackay I.R., Van De Water J., Gershwin M.E. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 2001, 120:1485-1501.
23. Kobayashi E., Kobayashi M., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci. 2009, 111:302-310.
24. Kobayashi M., Higuchi S., Ide M., Nishikawa S., Fukami T., Nakajima M., Yokoi T. Th2 cytokine-mediated methimazole-induced acute liver injury in mice. J. Appl. Toxicol. 2012, 32:823-833.
25. Kobayashi M., Higuchi S., Mizuno K., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Interleukin-17 is involved in α-naphthylisothiocyanate-induced liver injury in mice. Toxicology 2010, 275:50-57.
26. Kumada T., Tsuneyama K., Hatta H., Ishizawa S., Takano Y. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod. Pathol. 2004, 17:1141-1149.
27. Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., Devera M.E., Liang X., Tor M., Billiar T. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 2007, 220:60-81.
28. Maltzman J., Koretzky G. Azathioprine: old drug new actions. J. Clin. Invest. 2003, 111:1122-1124.
29. Marinaki A.M., Ansari A., Duley J.A., Arenas M., Sumi S., Lewis C.M., Shobowale-Bakre el-M., Escuredo E., Fairbanks L.D., Sanderson J.D. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004, 14:181-187.
30. Oo Y.H., Adams D.H. The role of chemokines in the recruitment of lymphocytes to the liver. J. Autoimmun. 2010, 34:45-54.
31. Petit E., Langouet S., Akhdar H., Nicolas-Nicolaz C., Guillouzo A., Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol. In Vitro 2008, 22:632-642.
32. Savov J.D., Brass D.M., Lawson B.L., McElvania-Tekippe E., Walker J.K., Schwartz D.A. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am. J. Physiol. Lung Cell Mol. Physiol. 2005, 289:L329-L337.
33. Steinman L. A brief history of Th17, the first major revision in the Th1/Th2 hypothesis if T cell-mediated tissue damage. Nat. Rev. Med. 2007, 13:139-145.
34. Takatsu N., Matsui T., Murakami Y., Ishihara H., Hisabe T., Nagahama T., Maki S., Beppu T., Takaki Y., Hirai F., Yao K. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 2009, 24:1258-1264.
35. Thornalley P.J. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell. Mol. Biol. 1998, 44:1013-1023.
36. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 1969, 27:502-522.
37. Tracey K.J. Tumor necrosis factor-α. The Cytokine Handbook 1994, 289-304. Academic Press, London. A. Thomson (Ed.).
38. Van Asseldonk D.P., Seinen M.L., De Boer N.K., Van Bodegraven A.A., Mulder C.J. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. J. Crohns Colitis 2012, 6:95-101.
39. Wang H., Yang H., Tracey K.J. Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med. 2004, 255:320-331.
40. Wong D.R., Derijks L.J., den Dulk M.O., Gemmeke E.H., Hooymans P.M. The role of xanthine oxidase in thiopurine metabolism: a case report. Ther. Drug Monit. 2007, 29:845-848.
41. Yano A., Higuchi S., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. Toxicology 2012, 293:107-114.
42. Yao D., Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59:249-255.
43. Zhao X., Zhu J.X., Mo S.F., Pan Y., Kong L.D. Effects of cassia oil on serum and hepatic uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. J. Ethnopharmacol. 2006, 103:357-365.